Somalogic, Incorporated

Ribozyme Pharmaceuticals, Incorporated

Crestone, Inc.

Other

University of Colorado

Otsuka Pharmaceutical Company, Limited

Sirna Therapeutics, Inc.

Replidyne, Inc.

Biovector Therapeutics, S.a.

Thale Jarvis

Nebojsa Janjic

James A McSwiggen

John C Rohloff

Dan T Stinchcomb

Amy D Gelinas

Sheela M Waugh

Xicheng David Sun

Daniel W Drolet

Chi Zhang

Leonid Beigelman

Larry M Gold

Daniel J Schneider

Jasenka Matulic-Adamic

Alexander Karpeisky

Sarah A Strong

Sheri K Wilcox

Joseph Guiles

Kenneth G Draper

Jian Qiu

Bruce Eaton

Nassim Usman

Dominic Zichi

Francine E Wincott

Chris Bock

Anthony DiRenzo

Jeffrey D Carter

Tod M Woolf

James D Thompson

Urs Ochsner

Peter Haeberli

Pamela Pavco

Laurent Bellon

Frank B Dean

James M Graham

Ignacio De Miguel

Didier Betbeder

Shashi Gupta

Roger Kravtzoff

Deborah Ayers

Mark Reynolds

Charles S McHenry

James M Bullard

Michael Riel-Mehan

Glenn Sanders

Stacie Bell

Masao Hirota

Michael Zwick

Tomoki Suzuki

Joshua Day

Yuichi Ishikawa

Elizabeth Mcfaddin

Christina Wong

Ikuo Murakami

Sophie Sixou

Garry Dallmann

Sheri Wilcox

The present invention provides novel heterocylic amide compounds having useful antimycobacterial activity. Use of these compounds as pharmaceutical compositions and method of their production are also provided.

Antimycobacterial heterocyclic amides

The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose lung cancer or permit the differential diagnosis of pulmonary nodules as benign or malignant. In another aspect, methods are provided for diagnosing lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 18, Table 20, or Table 21, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.

Lung cancer biomarkers and uses thereof

Aptamers that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are provided, as well as methods of treating conditions using the aptamers and aptamer constructs.

Post-selex modification methods

Post-selec modification methods

Aptamers to PDGF and VEGF and their use in treating PDGF and VEGF mediated conditions

The present disclosure describes the identification and use of aptamers and photoaptamers having slower dissociation rate constants than those obtained using previously described methods. Specifically, the present disclosure describes methods for the identification and use of aptamers to one or more targets within a histological or cytological sample, which have slow rates of dissociation. The aptamers may be used to assess localization, relative density, and presence or absence of one or more targets in cytological and histological samples. Targets may be selected that are specific and diagnostic of a given disease state for which the sample was collected. The aptamers may also be used to introduce target specific signal moieties. In addition to target identification, the aptamers may be used to amplify signal generation through a variety of methods.

Method for generating aptamers with improved off-rates

Aptamers that bind IL-6 are provided. Pharmaceutical compositions comprising IL-6 aptamers are provided, as well as methods of treating conditions using the aptamers are also provided.

Aptamers that bind to IL-6 and their use in treating or diagnosing IL-6 mediated conditions

The present invention provides novel heterocyclic urea compounds having useful antibacterial activity, pharmaceutical compositions comprising one or more of these compounds, methods of making the same, and methods of using the same.

Antibacteriall heterocyclic ureas

Reconstituted bacterial replication assemblies and methods for their use are provided.

Bacterial replication systems and methods

The present invention provides novel sulfone and sulfoxide substituted heterocyclic urea compounds having useful antibacterial activity. Use of these compounds as pharmaceutical compositions and methods of production are provided.

Antibacterial sulfone and sulfoxide substituted heterocyclic urea compounds

The present invention provides novel amide and sulfonamide substituted heterocyclic urea compounds having useful antibacterial activity. Use of these compounds as pharmaceutical compositions and method of their production are also provided.

Antibacterial amide and sulfonamide substituted heterocyclic urea compounds

This invention relates to novel chemically-modified nucleic acid molecules having specific formulae that exhibit increased resistance to nucleases and increased binding affinity to target nucleic acid molecules. The invention further relates to methods of modulating gene expression using the novel chemically modified nucleic acid molecules, and compositions and cells comprising said molecules.

Nucleic acid molecules with novel chemical compositions capable of modulating gene expression

An enzymatic nucleic acid molecule comprising a 5&prime;- and/or a 3&prime;-cap structure, wherein said structure is not a 5&prime;-5&prime;-linked inverted nucleotide or a 3&prime;-3&prime;-linked inverted nucleotide.

Enzymatic nucleic acids containing 5&prime;-and or 3&prime;-cap structures

Growing community of inventors

Boulder, CO, United States of America

Thale Jarvis